Two novel TSC2 frameshift mutations in tuberous sclerosis complex.
- Author:
Yu-Chun PAN
1
;
Wei-Qing WU
;
Jian-Sheng XIE
;
Cai-Qun LUO
;
Ying HAO
Author Information
1. Prenatal Diagnosis Center, Shenzhen Maternity and Child Health Care Hospital, Southern Medical University, Shenzhen, Guangdong 518000, China. jsxieszmch@aliyun.com.
- Publication Type:Journal Article
- MeSH:
Child;
Child, Preschool;
Female;
Frameshift Mutation;
Humans;
Tuberous Sclerosis;
genetics;
Tumor Suppressor Proteins;
genetics
- From:
Chinese Journal of Contemporary Pediatrics
2017;19(3):308-312
- CountryChina
- Language:Chinese
-
Abstract:
High-throughput sequencing was performed for the peripheral blood DNA from two probands in the family with tuberous sclerosis complex (TSC) to determine the sequences of TSC-related genes TSC1 and TSC2 and their splicing regions and identify mutation sites. Amplification primers were designed for the mutation sites and polymerase chain reaction and Sanger sequencing were used to verify the sequences of peripheral blood DNA from the probands and their parents. The two probands had c.3981-3982 insA (p.Asp1327AspfsX87) and c.4013-4014 delCA (p.Ser1338Cysfs) heterozygous mutations, respectively, in the TSC2 gene. The parents of proband 1 had no abnormalities at these two loci; the mother of proband 2 had c.4013-4014 delCA heterozygous mutation in the TSC2 gene, while the father and the grandparents of proband 2 had no abnormalities. c.3981-3982 insA mutation may cause early coding termination of amino acid sequence at the 1413th site, and c.4013-4014 delCA mutation may cause early coding termination of amino acid sequence at the 1412th site. These two mutations are the pathogenic mutations for families 1 and 2, respectively, and both of them are novel frameshift mutations, but their association with the disease needs to be further verified by mutant protein function cell model and animal model.
